Investing.com - LAVA Therapeutics NV reported on Wednesday third quarter earnings that beat analysts' forecasts and revenue that topped expectations.
LAVA Therapeutics NV announced earnings per share of $0.04 on revenue of $15.26M. Analysts polled by Investing.com anticipated EPS of $-0.57 on revenue of $333.33K.
LAVA Therapeutics NV shares are down 12% from the beginning of the year and are trading at $4.80 , down-from-52-week-high.
LAVA Therapeutics NV follows other major Healthcare sector earnings this month
LAVA Therapeutics NV's report follows an earnings beat by Eli Lilly on November 1, who reported EPS of $1.98 on revenue of $6.94B, compared to forecasts EPS of $1.91 on revenue of $6.91B.
Pfizer had beat expectations on November 1 with third quarter EPS of $1.78 on revenue of $22.6B, compared to forecast for EPS of $1.44 on revenue of $21.33B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar